The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | 6-year follow-up of ELEVATE-TN: sustained safety and efficacy in CLL
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, reports a six-year follow-up on the ELEVATE-TN trial (NCT02475681), comparing acalabrutinib ± obinutuzumab (A ± O) to obinutuzumab + chlorambucil (O + Clb) in patients with treatment-naïve chronic lymphocytic leukemia (CLL). The analysis revealed sustained safety and efficacy in A+O and O treated patients, with prolonged progression-free survival (PFS) in patients treated with A+O versus A, and prolonged overall survival (OS) in patients treated with A+O versus O+Clb. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Newave, Loxo, Beigene, AstraZeneca, Abbvie, Janssen, Pharmacyclics
Research Funding; Schrodinger, Morphosys, Karyopharm, Janssen, Pharmacyclics
